RARE vs SRPT
RARE: Ultragenyx is a biopharmaceutical company dedicated to transforming the lives of patients suffering from rare and ultra-rare genetic diseases through innovative therapeutic development. SRPT: Sarepta Therapeutics is a leader in genetic medicine, specializing in innovative RNA-targeted and gene therapies to treat rare neuromuscular diseases like Duchenne muscular dystrophy.
Side-by-side fundamentals
| Metric | RARE | SRPT | Edge |
|---|---|---|---|
| Price as of 2026-08-21 close | $25.83 | $18.79 | |
| Market cap as of 2026-08-25 | $2.5B | $2.0B | |
| PEG as of 2026-08-25 | -0.78 | -21.22 | SRPT lower |
| Net margin as of 2026-08-25 | -81.7% | -6.9% | SRPT higher |
| Gross margin as of 2026-08-25 | +83.1% | +67.5% | RARE higher |
| Operating margin as of 2026-08-25 | -73.7% | -6.4% | SRPT higher |
| ROE as of 2026-08-25 | -414.2% | -10.0% | SRPT higher |
| ROA as of 2026-08-25 | -44.4% | -4.1% | SRPT higher |
| Debt / equity as of 2026-08-25 | 90.54 | 0.55 | SRPT lower |
| Revenue growth (YoY) as of 2026-08-25 | +17.5% | -20.4% | RARE higher |
| Revenue CAGR (3y) SEC XBRL | +22.8% | +33.1% | SRPT higher |
| Dividend streak (yrs) SEC XBRL | 0 | n/a | |
| Beta as of 2026-08-25 | 0.28 | 0.34 | |
| 1-year return as of 2026-08-21 close | -12.5% | -6.3% | SRPT higher |
Fundamentals: market data, as of 2026-08-25. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.